NGEN -- Awarded Patents for Biomarkers Associated with Diabetes, Alzheimers Disease
SAN DIEGO--(BUSINESS WIRE)--
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it has been issued four patents by the U.S. Patent and Trademark Office for inventions related to diabetes and Alzheimers disease biomarkers. The current patents are the most recent in a series describing biomarkers associated with these diseases.
U.S. Patent No. 7,179,610, "Complement C3 precursor biopolymer markers indicative of insulin resistance," and U.S. Patent No. 7,132,244, "Betaine/GABA transport protein biopolymer marker indicative of insulin resistance," describe the use of mass spectrometry and time-of-flight detection techniques to identify biopolymers that could potentially be used in the diagnosis of or development of therapeutics for the metabolic conditions Syndrome X and type II diabetes.
U.S. Patent No. 7,179,605, "Fibronectin precursor biopolymer markers indicative of Alzheimer's disease," and U.S. Patent No. 7,179,606, "IG heavy chain, IG kappa, IF lambda biopolymer markers indicative of Alzheimer's disease," relate to the identification of protein biomarkers for Alzheimer's disease.
For information about licensing opportunities, contact Nanogen.
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip(R) electronic microarray platform and a line of rapid diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen's website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Source: Nanogen, Inc.
